FY2025 EPS Estimates for Novartis Boosted by Zacks Research

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of Novartis in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $8.33 per share for the year, up from their previous forecast of $8.31. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q4 2025 earnings at $2.08 EPS, Q3 2026 earnings at $2.39 EPS and Q4 2026 earnings at $2.24 EPS.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the previous year, the firm earned $1.74 earnings per share.

Other equities research analysts also recently issued research reports about the company. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Down 0.4 %

Shares of NYSE NVS opened at $97.51 on Friday. The stock has a market capitalization of $199.30 billion, a PE ratio of 11.32, a P/E/G ratio of 1.36 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The firm has a fifty day moving average of $100.61 and a 200-day moving average of $108.98. Novartis has a 52-week low of $92.35 and a 52-week high of $120.92.

Institutional Investors Weigh In On Novartis

Hedge funds have recently modified their holdings of the stock. Wealth Alliance raised its stake in shares of Novartis by 5.5% during the second quarter. Wealth Alliance now owns 3,683 shares of the company’s stock valued at $392,000 after purchasing an additional 191 shares during the period. Mercer Global Advisors Inc. ADV grew its position in shares of Novartis by 3.6% during the second quarter. Mercer Global Advisors Inc. ADV now owns 153,055 shares of the company’s stock worth $16,294,000 after buying an additional 5,285 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of Novartis by 19.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 69,774 shares of the company’s stock worth $7,324,000 after buying an additional 11,355 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Novartis in the second quarter valued at $22,979,000. Finally, Seven Eight Capital LP boosted its stake in Novartis by 229.8% during the 2nd quarter. Seven Eight Capital LP now owns 13,647 shares of the company’s stock valued at $1,453,000 after acquiring an additional 9,509 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.